| 1 |
35505771 | Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease. | 2022 Jan |
1 |
| 2 |
33517393 | Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy. | 2021 Apr 26 |
1 |
| 3 |
34471993 | Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. | 2021 Oct |
1 |
| 4 |
31833760 | "Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4": Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping. | 2020 Feb 17 |
1 |
| 5 |
31956784 | Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases. | 2020 Jan 14 |
1 |
| 6 |
32539713 | JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells. | 2020 Jun 15 |
2 |
| 7 |
30806707 | Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. | 2019 Feb 1 |
1 |
| 8 |
30872773 | Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis. | 2019 Mar 14 |
1 |
| 9 |
31288716 | Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors. | 2019 |
2 |
| 10 |
31375130 | Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. | 2019 Aug 2 |
1 |
| 11 |
29452839 | Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. | 2018 May 1 |
1 |
| 12 |
29471605 | [Emerging Therapies: What Are Promising in the Near Future?] | 2018 Feb 25 |
1 |
| 13 |
29942363 | The role of the JAK/STAT signal pathway in rheumatoid arthritis. | 2018 Jun |
2 |
| 14 |
30157949 | Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils. | 2018 Aug 29 |
2 |
| 15 |
27771180 | Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors. | 2017 Jan 1 |
1 |
| 16 |
28387906 | Facilitation of liver cancer SMCC7721 cell aging by sirtuin 4 via inhibiting JAK2/STAT3 signal pathway. | 2017 Mar |
2 |
| 17 |
28790099 | GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis. | 2017 Aug 7 |
1 |
| 18 |
28829236 | A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. | 2017 Oct |
1 |
| 19 |
25027606 | Novel treatments with small molecules in psoriatic arthritis. | 2014 |
1 |
| 20 |
25057499 | Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. | 2014 |
1 |
| 21 |
25217444 | Selective inhibitors of the Janus kinase Jak3--Are they effective? | 2014 Oct 1 |
2 |
| 22 |
23849222 | Tofacitinab in renal transplantation. | 2013 Jul |
2 |
| 23 |
24326545 | The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. | 2013 Dec |
1 |
| 24 |
20478313 | Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. | 2010 Jul 16 |
1 |
| 25 |
18482053 | The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. | 2008 Jun |
4 |